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Summary In this review we have summarized our experiences of serological analysis of MHC class II antigen
expression in human B cell malignant disease. Cells from a large number of cases of B-cell chronic
lymphocytic leukaemia (CLL) and non-Hodgkin's lymphoma (NHL) have been examined for expression of
class II antigens. Using a number of monoclonal antibodies which in some cases are specific for class II
subregion products (DP, DQ and DR), MHC class II antigens were detected by indirect immunofluoresence
and fluorescent activated cell sorter analysis in CLL and by immunohistochemical staining in NHL. At the
cell surface in many cases of B cell malignant disease, products of the different class II subregion genes are
non-coordinately expressed. The most commonly occurring pattern of non-coordinate expression of class II
molecules is of expression of DP and DR antigens in the absence of detectable DQ expression. These findings
are in contrast to normal B lymphocytes where DP, DQ and DR antigens are expressed together at the
cell surface. There is considerable heterogeneity among cases comprising individual histopathological
categories of B cell malignancy, and in many instances heterogeneous class II phenotypes are also found on cells
from the same tumour. In chronic lymphocytic leukaemia, class II antigen expression is inducible in vitro by
treating the cells with the phorbol ester TPA. CLL cells treated with TPA have much increased levels of class
II antigen expression at the cell surface and much increased steady state levels of class II specific mRNA
transcripts detectable with complementary DNA probes. Aberrant class II antigen expression may be involved
in the pathogenesis of B cell malignant disease.
Suggestions that human MHC class II antigens
might be differentiation markers of leukaemic cells
(Schlossman et al., 1976), and the demonstration
that class II antigen expression is lost at the
terminal stages of B cell differentiation, in both
normal and malignant cells (Halper et al., 1978)
date back almost a decade. These findings preceded
the realization that MHC class II antigens are
encoded by a large number of genes (Korman et
al., 1985; Trowsdale et al., 1985). Recent detailed
molecular studies of the structure of class II
antigens (Giles & Capra, 1985), and their genes
(Gustafsson et al., 1984), and the availability of
monoclonal antibodies recognizing specific products
of the different class II loci (Bodmer & Bodmer,
1984), have stimulated further interest in
differentiation-related expression of class II antigens
in cells of the B lymphoid series. These more recent
advances offer means to examine in detail, the
mechanisms regulating expression of class II
antigens. The large numbers of immature cells from
the peripheral blood of patients with B cell
leukaemia, are an especially valuable source
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of material for serological and molecular studies of
phenotypic change during B cell differentiation.
The MHC class II antigens are important immuno-
regulatory molecules, and knowledge of their
expression in B cell leukaemia and lymphoma may
enhance understanding of the processes of
malignant change.
In this review we (i) summarize our experiences
in the serological analysis of class II antigen
expression in B-cell leukaemia and lymphoma and
(ii) try to address the possible functional con-
sequences of apparently aberrant expression of the
antigens in the pathogenesis of human B cell
malignant disease. As a preliminary to this, the
structure of MHC class II antigens, their expression
in normal tissues, and recent findings on the
specificity of monoclonal antibodies directed to
class II antigens are reviewed very briefly.
Structure and genetic organization of MHC class II
antigens
The genetic organization of human MHC class II
antigens is exceedingly intricate. Class II antigens
are encoded within a segment of the major histo-
© The Macmillan Press Ltd., 1986162 K. GUY et al.
compatibility complex (MHC) on the short arm of
chromosome 6. At the cell surface, class II
molecules are heterodimers consisting of alpha
chains of -34,000 mol. w and beta chains of
,29,000mol.,w. MHC class II genes are organized
in three subregions (loci), now known as DP, DQ
and DR. Each subregion comprises several genes
and encodes one or more structurally distinct and
polymorphic cell surface class II heterodimers
(reviewed by Giles & Capra, 1985). The DP, DQ
and DR beta chain genes and their products, as
well as the DQ alpha chains, are highly
polymorphic (reviewed by Giles & Capra, 1985;
Korman et al., 1985; Trowsdale et al., 1985). In the
case of the DQ subregion, where both alpha and
beta chains are polymorphic, the repertoire of class
II antigens expressed may also be influenced by
transcomplementary association of alpha chains of
one DQ allele with beta chains of the other, to
form hybrid molecules (Giles et al., 1985). The
numbers of genes and correspondingly, the numbers
of expressed heterodimers, may also vary in
different haplotypes. These considerations, of
polymorphism and differences in the numbers of
expressed class II antigens in different haplotypes,
make their detection difficult, especially when
products of the DP and DQ loci are sought. This is
despite the substantial number of available mono-
clonal antibodies directed to class II antigens. To
add to this complexity, the number of class II genes
may be greater than is presently established
(Trowsdale & Kelly, 1985).
Monoclonal antibodies to human MHC class II
antigens
In many studies on differentiation-related
expression of class II antigens, monoclonal
antibodies directed to so-called 'framework', non-
polymorphic determinants of class II antigens have
been used. Original concepts of framework
determinants of class II molecules envisaged a
limited number of antigenic determinants common
to all individuals and present on the products
of all the class II genes. Some of the frame-
work determinant-directed antibodies have been
shown to react with isolated alpha or beta chains
(Guy et al., 1982). Many antibodies regarded as
framework-specific are now known to recognize
only a proportion of the total class II pool of
molecules. For example, a number of antibodies
recognize DP and DR molecules but not DQ
molecules (Shaw & DeMars, 1984; Shaw et al.,
1985). Determinants recognized as the specific
products of one locus in a given haplotype may be
encoded by other class II genes in other haplotypes
(Goyert & Silver, 1983). This level of complexity
means that the results obtained with some anti-
bodies to MHC class II antigens are corres-
pondingly difficult to interpret satisfactorily.
Monoclonal antibodies to framework determinants
continue to be very useful in routine histo-
pathological classification of lymphoid malignancy
and may identify areas for detailed analysis with
other more 'specific' anti-class II antibodies.
However, the problems of adequately defining
specificityplace severeconstraints onthe usefulness of
anti-frameworkantibodies inidentifyingexpressionof
products of a particular locus by serological means.
Defining class II expression in terms of specific
products ofdifferent subregions is important because
the antigens may have different functions.
Recently, a number of monoclonal antibodies
recognizing determinants confined in expression to
products of a single class II subregion have become
available. Some of these antibodies have been
extensively tested in different MHC haplotypes
(Brodsky, 1984; Crumpton et al., 1984). The
antibodies currently used in our own studies of
class II expression in human B cell malignancy are
listed in Table I.
Expression of MHC class II antigens in normal
tissues
A detailed knowledge of the expression of class II
antigens in normal tissue is essential for the
interpretation of results of studies on B cell
malignancy, and in assessing possible effects of
neoplastic change on the expression of these
antigens. Class II antigens are predominantly
expressed in cells of the B lymphocyte and the
monocyte/macrophage series, although studies have
shown that they are not confined to these
tissues (Daar et al., 1984). In some tissues class II
expression is constitutive and in others, including a
variety of malignant cell lines derived from solid
tumours, is inducible with y-interferon or mitogens
(Shaw et al., 1985).
All normal peripheral blood B cells are class II
positive, and express coordinately products of DP,
DQ and DR loci (Nunez et al., 1984). On average,
- 35% of the monocytes in normal peripheral
blood are DR-positive and DQ-positive (Gonwa et
al., 1983; Guy et al., 1983a; Nunez et al., 1984),
and most of the remainder are DR-positive and
DQ-negative. It appears that only DR+DQ+
monocytes are functionally active in antigen
presentation (Gonwa et al., 1983). Products of the
DR and DQ loci are also non-coordinately
expressed on activated T cells (Brown et al., 1984).MHC CLASS II ANTIGENS IN B CELL MALIGNANCY 163
Table I The specificities of anti-human MHC class II
antibodies
Monoclonal
antibody Specificity Source Reference
DA6.231 DP+DQ+DR Guy et al., 1982
TU39 DP+DQ+DR Pawelec et al., 1982
L243 DR Lampson & Levy, 1980
DA6.164 DR van Heyningen et al., 1982
DA6.147 DR+DQ Guy et al., 1982
TU22 DQ Pawelec et al., 1982
BT3/4 DQ Corte et al., 1981
LeulO DQ Brodsky, 1984
B7/21 DP Watson et al., 1983
A variety of techniques have been used to determine
the specifities of anti-human MHC class II reagents.
These include two-dimensional polyacrylamide gel electro-
phoresis (Crumpton et al., 1984) and serological tests
against deletion mutant cell lines (Shaw & De Mars, 1984)
which have lost selectively the expression of products
of one or more class II subregions. The specificities
assigned above are intended to reflect the predominant
pattern of reaction of the antibodies and these have
usually been determined by tests on only a limited number
of haplotypes. A few reagents, such as BT3/4, L243 and
Leu 10 have been extensively characterized on cells
representing most of the recognized DR alleles (Brodsky,
1984). Because of the intricacy of the human class II
region, it is possible that the subregion products
recognized by the antibodies may vary on different MHC
haplotypes. The assigned specificities should therefore be
regarded only as provisional. DA6.147 reacts with isolated
alpha chains, DA6.231, TU39 and DA6.164 react with
beta chain determinants.
Immunohistochemical analysis of tissue sections
and fluoresence activated cell sorter analysis of cell
suspensions from peripheral lymphoid tissues
(spleen, lymph node and tonsil) have similarly
shown coordinate expression of DQ and DR
antigens by most normal B cells (Hsu et al., 1984;
Marti et al., 1985; Krajewski et al., 1985). In all
embryonic tissues studied, where there is expression
of class II antigens, DR antigens appear
before DQ antigens (Natali et al., 1984). DP
antigen expression, in the absence of DR and DQ
expression, is also reported to occur on early
embryonic lymphopoietic tissues (Edwards et al.,
1985; Muller et al., 1985). Thus, these studies
demonstrate that coordinate expression of DP, DQ
and DR antigens occurs on most normal B cells
and that non-coordinate expression of class II
antigens is a feature of some other normal tissues.
Expression ofMHC class II antigens in B-cell
chronic lymphocytic leukaemia
Class II expression in B cell chronic lymphocytic
leukaemia (CLL) is heterogeneous, both from cell to
cell within individual cases and also among cells
from different patients (Okamura et al., 1982;
Addis et al., 1982; van Heyningen et al., 1982).
Class II antigens are expressed on almost all B cells
from the peripheral blood of all B cell CLL patients
(Halper et al., 1979; Newman & Greaves, 1982;
Okamura et al., 1982a; Guy et al., 1983a).
However, although the cells of all patients express
DR antigens there is detectable expression of DP
and DQ antigens on only a proportion of the cells
in some cases (Figure 1) (Guy et al., 1983a;
Swerdlow et al., 1984; Marti et al., 1985; Guy et al.,
1986a). The proportion of cells which is DP, DQ
and DR-positive is highly variable from patient to
patient. In many patients, cells expressing DP, DQ
and DR antigens are the major population, and in
others such cells comprise as little as 20% of the
total, the remaining cells being DR-positive and
DP/DQ-negative. In most cases of CLL the
numbers of DP-positive cells are equal to the
numbers of DQ-positive cells (although in the
example illustrated there are a few more DP- than
DQ-positive cells). In no instance have we found
expression of DP or DQ antigens without
expression of DR antigens. The small and variable
numbers of normal B cells in the circulation of
CLL patients may comprise some of the cells
coordinately expressing DP, DQ and DR antigens.
On average - 5% of the cells in B cell CLL are T
lymphocytes, and these may comprise some of the
class II-negative cells. In a number of cases of CLL,
cells have been cultured with the phorbol ester
TPA, resulting in very much increased levels of
class II expression (vide infra).
Expression of MHC class II antigens in B-cell non-
Hodgkin's lymphoma
Immunohistochemical studies of non-Hodgkin's
lymphoma (NHL) show marked heterogeneity of
class II expression (Krajewski et al., 1985) similar to
that seen in CLL. Of the 84 cases of NHL that we
have now examined (Table II), more than half show
evidence of non-coordinate expression of class II
antigens. In general terms, many clinically high
grade centroblastic and immunoblastic lymphomas
express coordinately DP, DQ and DR antigens and
failure to express DQ antigens on a significant
proportion of the cells is commonly a feature of the
low grade lymphomas (Table II). The only major
difference in the results of class II expression
among cases of CLL and NHL concerns the
expression of DP antigens. DP antigens are usually
detectable on most of the DR-positive cells in NHL
(Table III), whereas DP-positive cells more often164 K. GUY et al.
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comprise a minority of the DR-positive population
in CLL. It is possible that MHC class II expression
is influenced by differences in proliferative activity
of low grade and high grade lymphomas (Srigley et
al., 1985).
The most marked difference in expression of DR
and DQ antigens so far found in NHL is in cases
of centrocytic lymphoma: cells from five of seven
patients fail to react with anti-DQ antibodies. In
common with much earlier studies (Halper et al.,
1978) in plasmacytomas, representative of the
terminal stages of B cell differentiation, class II
expression is usually weak or not detectable.
Discrepancies in reactivity between monoclonal
antibodies detecting different determinants of DR
antigens is sometimes found in NHL (Table III).
This is probably a result of the extensive poly-
morphism of class II antigens and is reflected in
distinct haplotype preferences for binding of certain
monoclonal antibodies (Shaw & DeMars, 1984).
For example, DA6.164 does not react with DR7
(van Heyningen et al., 1982) and has higher affinity
for DR3 and DR5 cells than for cells of other DR
types (unpublished results). These observations
emphasize the necessity for using a panel of
monoclonal antibodies when assessing class II
expression and for caution in interpreting data even
when a number of antibodies have been used.
There may be an alternative explanation for the
discepancies in the reactions of some anti-class II
antibodies, such as DA6.164 and L243: the
predominant reaction of DA6.164 is for a product
of one of the number of DR encoded beta poly-
peptides (Crumpton et al., 1984), whereas L243
recognizes all DR polypeptides in the haplotypes
Figure 1 Cells from a CLL patient (JT) examined by
indirect immunofluoresence and fluoresence activated
cell sorter (FACS IV) as previously described
(Guy et al., 1986b) using anti-class II antibodies
described in Table 1 (a-d) and the anti-class I
antibody MHM5 (e). Negative control peaks of cells
stained with an irrelevant antibody (anti-alphafeto-
protein) are on the left hand side of each graph. Cell
numbers per channel is on the vertical axis and
fluorescence intensity (logarithmic amplification) is on
thehorizontal axis(totalscaleof256channels).Theresult
shown is representative of about 15-20% of all CLL
examined in the present series (Guy et al., 1986a,b).
Other cases have higher and variable numbers of DP
and DQ-positive cells (cf. Figure 2). In patient JT,
although only a minority of the cells are DP-positive
(31%) and DQ-positive (22%; controls 2%) some of
the cells are strongly DQ-positive (in channels 60-100).
Cells from JT have also been treated with TPA (Guy
et al., 1986a) and DQ expression is increased >20
fold. In all cases of CLL after culture with TPA, DP
and DQ antigens are expressed on >85% of the cells.MHC CLASS II ANTIGENS IN B CELL MALIGNANCY 165
Table II Immunohistochemical staining of B-cell non-Hodgkin's lymphoma (84
cases): ComparisonofstainingwithDA6.231 (DP+DQ+DR)andLeuIO/TU22(DQ)
Cells stainedfor:
Histopathological DP+DQ+DR DQ
classification (DA6.231) (Leu1O/TU22)
Low grade
Lymphocytic (13)1
Lymphoplasmacytic (3)
Prolymphocytic (3)
Centrocytic small cell (6)
Centrocytic large cell (1)
Hairy cell leukaemia (3)
Centroblastic-centrocytic
follicular (17)
diffuse (6)
High grade
Centroblastic (20)
Immunoblastic (5)
Plasmacytoma (3)
Lymphoblastic (4)
+ + +
+ + +
+ + +
+ + +
+ + +
+ +
+ + +
+ + +
+ + +
+ + +
+ + +
+ + +
+ + +
+ + +
+ + +
+ + +
+ + +
+ + +
+++
++
neg
+ + (5)
+ (5)
neg (3)
+++ (1)
+ (1)
+ + (1)
+++ (1)
+ + (2)
+ (1)
neg (5)
+++ (1)
+++ (2)
neg (1)
+++ (7)
+ + (9)
+ (1)
+++ (4)
+ + (2)
+++ (14)
+ + (1)
+ (1)
neg (1)
neg (3)
+++ (4)
+ + (1)
+ (1)
neg (2)
+++ (1)
+ + (1)
+ (1)
neg (1)
aNumber of cases in each category; + + + = >70% of the cells staining;
+ +30-70%; +5-30%; neg<5% cells staining.
Cases were classified histologically using the Kiel Classification.
Immunoperoxidase staining and scoring of frozen sections of tumour tissue was
carried out as previously described (Krajewski et al., 1985).
All cases were defined as B cell lymphoma by demonstrating staining with
B-lineage specific monoclonal antibodies (Dako B or Coulter B1) and/or by
demonstrating staining for immunoglobulin with light chain restriction.
Cases of lymphoblastic lymphoma all showed strong staining with J5 (CALLA)
and with Dako B, but only one case stained for immunoglobulin (MA).
Cells were stained for total class II-positive cells with DA6.231
(DP+DQ+DR) and with TU22 and LeulO (DQ-specific). TU22 and LeulO gave
identical results in all cases.166 K. GUY et al.
Table HI Immunohistochemical staining of B-cell non Hodgkin's lymphoma with a panel of anti-class II monoclonal
antibodies
Cells stainedfor:
Histopathological DP+DQ+DR DP DR DR DR+DQ DQ DQ
classification (DA6.231) (B7/21) (L243) (DA6.164) (DA6.147) (LeulO) (TU22)
Lymphocytic +++ +++ ++ ++ ++ ++ ++
Lymphocytic +++ +++ +++ +++ ++ ++ ++
Lymphocytic + + + + + + + + + + + + + neg neg
Centrocytic (small cell) + + + + + + + + + + + + + neg neg
Centrocytic (small cell) + + + + + + + + + + + + +
Centrocytic(large cell) + + + + + + nd + + + + + + + + + +
Hairy cell leukaemia + + + + + + + + neg + + + neg neg
Hairycellleukaemia +++ +++ +++ +++ +++ +++ +++
Hairycellleukaemia +++ +++ +++ +++ +++ +++ +++
CB/CC-follicular + + + + + + ++ +++
CB/CC-follicular + + + + + nd + + + +
CB/CC-follicular +++ +++ +++ +++ ++ ++ +++
CB/CC-follicular + + + + + + + + + + + + + + +
CB/CC-diffuse +++ +++ nd +++ +++ +++ +++
Centroblastic + + + +++ + neg neg neg neg
Centroblastic + + + + + + + + neg + + + neg neg
Centroblastic + + + + + + + + neg neg + ++ +++
Immunoblastic +++ +++ +++ +++ +++ +++ +++
Immunoblastic +++ +++ +++ +++ +++ +++ +++
Immunoblastic +++ +++ +++ +++ +++ +++ +++
Immunoblastic + + + + + nd + + + + + + + + +
Plasmacytoma + + + + + + + + +
Plasmacytoma neg neg neg neg neg neg neg
Plasmacytoma neg neg neg neg neg neg neg
Lymphoblastic +++ +++ +++ +++ +++ ++ ++
Lymphoblastic + + + + + + + + + +
CB/CC=centroblastic/centrocytic;
staining.
nd=not done; neg=<5%; +=5-30%; ++=30-70%; +++=>70% cells
examined (Shackelford et al., 1982). This may
suggest that products of the different DR beta
chain genes are non-coordinately expressed. In all
cases of NHL examined in the present study the
anti-DQ antibodies TU22 and LeulO, which are
directed to different determinants, have given
equivalent results.
Expression of MHC class II antigens in hairy cell
leukaemia
Hairy cell leukaemia (HCL) is a rare variant of
lymphoid malignancy, in which the cells are
commonly of the B cell lineage (Hermann et al.,
1985). Faille and colleagues (1984) examined a
single case of HCL by biochemical means and
showed that the cells expressed DR antigens but
failed to express DQ antigens. DQ expression was
induced by treating the cells with TPA, sodium
butyrate or 5-azacytidine. We have examined five
subjects with hairy cell leukaemia and in all cases,
DR antigens are detectable on the majority of the
cells. In one case, sections of spleen have been
examined by immunohistochemistry and DQ
antigen expression is undetectable (Krajewski et al.,
1985). Two further cases examined by immuno-
histochemistry show coordinate expression of class
II antigens (Table III). In two other cases, in which
peripheral blood cells were examined by indirect
immunofluoresence, DQ and DP antigen expression
are detectable (in one case on almost all of the
cells) (Figure 2). Cells have also been examined
after culture with phorbol ester (vide infra).
In agreement with other studies (Korsmeyer et
al., 1983) we find readily detectable expression of
interleukin-2 receptor on HCL cells in tissue
sections and on peripheral blood cells in all cases.
Expression of MHC class II antigens in common
acute lymphoblastic leukaemia and in pre-B cell lines
Immunoglobulin gene rearrangements, and ex-
pression of cytoplasmic u chains (after stimulation
of ALL cells with phorbol ester) suggest that theMHC CLASS II ANTIGENS IN B CELL MALIGNANCY 167
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Figure 2 Cells from two cases of hairy cell leukaemia before and after culture of the cells with TPA. Cells
were analysed as described in Figure 1. In the first case (a), DP and DQ antigens are expressed on only a
proportion of the cells before culture (i-v) and class II expression is much increased after culture with TPA
(vi-x). In the second case (b), DP and DQ antigens are expressed on almost all of the cells before culture with
TPA (i-v). After culture with TPA (vi-x) class II expression is much reduced and this involves reduction of
DP, DQ and DR expression. DQ and DP expression are much reduced and detectable on only a very small
proportion of the cells. Interleukin 2 receptor (anti-Tac antibody) is detectable in both cases on the untreated
cells and is reduced in expression in both cases after culture of the cells with TPA.
cells in J5-positive, common acute lymphoblastic
leukaemia (ALL) are committed to differentiation
along a B cell pathway (Cossman et al., 1982).
There are apparently conflicting results on the
expression of class II antigens in ALL, although
there is no doubt that except in very rare cases,
class II antigens are expressed: Newman & Greaves
(1982) showed that of 556 cases of ALL examined
only 7 failed to express detectable levels of class II
antigens. We have examined only a small number of
ALL (van Heyningen et al., 1982; Guy et al., 1986a).
Nevertheless, it is obvious that heterogeneity of
class II expression is as much a feature of ALL
as it is of low grade leukaemia and other non-
Hodgkin's lymphoma. We and others find that
some ALL fail to express detectable levels of DP
and DQ antigens, although the same cells are
uniformly DR-positive (Newman et al., 1983; Guy168 K. GUY et al.
et al., 1986a). Other studies suggest that in some
cases of ALL there are more cells with detectable
expression of DP antigens than DR antigens
(Wernet et al., 1984) and that DQ expression
is confined to a minority of the DR-positive cells.
The finding of heterogeneity of cell surface class
II antigens in ALL is supported by quantitative
studies in 37 cases of ALL, where it was found
that the range of expression varied from patient to
patient by more than ten fold (Okamura et al.,
1984). Similar results have been reported
in CLL (Okamura et al., 1982a).
Non-coordinate expression of DR and DQ
antigens is also a feature of a number of established
lines derived from cases of ALL (Ziegler et al.,
1982; Newman et al., 1983; Wang et al., 1983).
That is, the majority of cells from the lines are DR-
positive and fewer cells are DQ-positive. In the
study of Wang et al. (1983) the monoclonal anti-
DP antibody ILR-1 was also reported to react with
the majority of cells in the lines.
MHC class 11 determinants as allelic markers of B
cell malignant disease
In a series of Edinburgh CLL patients studied, no
evidence was found that MHC class I or class II
antigens are markers of genetic suscep-
tibility to B cell malignant disease. There was an
association for a subgroup of patients lacking
HLA-A1 and B8 with less need for treatment
within a few months of diagnosis (Kilpatrick et al.,
1984). Other studies have described an association
between expression of the DQ determinant
recognized by the monoclonal antibody IVD12
(anti-DQw3) and CLL: in the study of Nunez-
Roldan et al. (1982), 93% of patients with CLL
were IVD12-positive (and DR4 or DR5-positive) in
comparison with 50% of controls. Linkage
disequilibrium accounts for the association of
DQw3 with DR4 and DR5. In the Edinburgh
study, only 40% of the patients, and an
equivalent number of controls, were DR4 and/or
DR5 positive (D.C. Kilpatrick, personal communi-
cation). The reasons for the discrepancy may be a
reflection of differences in the selection of patients,
classification of the disease or of the ethnic origins
of the subjects studied.
Stimulation of increased levels of MHC class II
antigen expression in CLL with phorbol ester
The croton seed oil tumour-promoting agent 12-0-
tetradecanoyl phorbol-13-acetate (TPA), introduced
several years ago (Totterman et al., 1980), has been
used widely in studies on malignant B cells. TPA is
an extremely powerful tool for dissecting events
contributing to differentiation of leukaemic cells.
The effects of TPA on morphology of CLL cells
and on their ability to secrete immunoglobulin are
consistent with induction of differentiation of the
cells (Totterman et al., 1980; Okamura et al.,
1982b). Cells from some patients, but not others,
enter S phase of the cell cycle after several days of
culture with TPA (Godal et al., 1982). In some
cases there is also secretion of considerable
quantities of immunoglobulin (reviewed by Gordon,
1984). In all cases, irrespective of whether the cells
enter S phase and/or secrete immunoglobulin, class
II expression is markedly increased by culture of
the cells with TPA (Totterman et al., 1981;
Okamura et al., 1982; Guy et al., 1983a, 1983b;
Guy et al., 1986a,b). The increases in class II
expression are highly variable from patient to
patient but appear to involve increased expression
of DP, DQ and DR antigens in all cases (Guy et
al., 1983a; Guy et al., 1986a,b). An example of CLL
cells examined before and after culture with
TPA for 72h is shown in Figure 3. In the example
illustrated, class II expression is increased about
five fold by culture with TPA. In other cases, where
class II expression is especially low on the untreated
cells, increments of more than twenty fold in DQ
expression are found (Guy et al., 1986a). In all
cases studied, DQ and DP antigens are detectable
on >85% of the cells after culture with TPA, even
in those cases where DP and DQ expression is
confined to about 20% of the cells before culture
(Guy et al., 1983a; Guy et al., 1986a). Transferrin
receptor and 4F2 expression are also increased by
TPA treatment of the cells but the expression of
Leu-1 is not substantially affected.
The appearance of increased levels of class II
antigens at the cell surface in CLL is a reflection of
increases in the steady state levels of class II
specific mRNA transcripts, detectable with comple-
mentary DNA probes specific for DP, DQ and DR
genes (Guy et al., 1986b; and unpublished results).
In samples examined from three patients, the levels
of class II specific mRNA transcripts detected with
cDNA probes parallel the levels of class II antigens
at the cell surface detected with monoclonal
antibodies. There is a need to establish in more
extensive studies if the serological differences in
class IIexpression atthecell surface arereflected atthe
mRNA level.
The proliferation centres of lymph node and
involved splenic white pulp areas in B cell
lymphocytic lymphoma preferentially stain with
anti-DQ antibodies, in comparison with the
surrounding cells, and as indicated previously
(Swerdlow et al., 1984) in this respect they areMHC CLASS II ANTIGENS IN B CEL MALIGNANCY 169
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Figure 3 Analysis of cells from a second CLL patient
(WT) illustrates the higher level of class II expression
on cells from some patients (cf. Figure 1) and the
increase in class II expression inducible with TPA.
Cells from WT have been examined on a number of
occasions and reported elsewhere (Guy et al., 1986a).
Cells were analysed as in Figure 1. About 50-60% of
the cells are DP- and DQ-positive before culture with
TPA (panels i-v) and >90% after culture (vi-x).
Expression of transferrin receptor (detected with
BK19/9) is also induced by culture with TPA and Leu-
1 (non-class II antigen CD5) expression is stable. The
increase in expression of class II antigens on cells of
WT has also been quantified by absorption: DQ
expression is increased about five fold and this
represents the minimum increase in DQ expression
seen in the present series after TPA activation of CLL
cells (Guy et al., 1986b).
similar to TPA-treated CLL cells. Recently we have
found that proliferation centres also express 4F2
and transferrin receptors (unpublished results).
It is difficult to determine how far towards the
terminal stages of differentiation CLL cells progress
after culture with TPA. A further problem lies in
distinguishing differentiation from activation of the
cells. Nevertheless, it is clear that cells from B cell
CLL patients are not in an intractable state of
maturation arrest. This implies that genes which are
important in controlling differentiation of the cells
are intact and have retained susceptibility at least in
vitro to epigenetic regulation.
Cells from two cases of hairy cell leukaemia
(HCL) have been tested after culture with TPA
(Figure 2). In one case class II expression is
increased and in the other class II expression is
substantially reduced. This is unexpected, because
class II expression after culture of CLL cells with
TPA is almost invariably increased. These findings
may suggest that some HCL (before culture with
TPA) are analogous to TPA-activated CLL cells,
and are close to terminal differentiation and loss of
class II expression, which then occurs when the
cells are cultured with TPA. Interleukin-2 (IL-2)
receptor expression is also reduced in HCL after
culture of the cells with TPA. The loss of IL-2
receptor is consistent with the suggestion that some
HCL are close to terminal differentiation, as is the
finding that plasma cell associated antigens are
expressed in HCL (cited in Hermann et al., 1985).
In only a single case of plasma cell leukaemia
have the effects of TPA on cells at the terminal
stages of B cell differentiation been tested (Guy et
al., 1986b). Class II expression is not induced in a
class II-negative, class I-positive plasma cell
leukaemia, suggesting that the ability to express
the antigens is irrevocably lost at the plasma
cell stage.
Cells from some patients with B cell leukaemia
respond to TPA stimulation with high rates of
immunoglobulin secretion. This will provide a
valuable source of material for the production of
anti-idiotype monoclonal antibodies for possible
therapeutic use.
Functional consequences of anomalous MHC class II
expression in B cell malignancy
A major mechanism which regulates the
interactions of cells comprising the immune system,
involves recognition of class II molecules through
specific receptors on the surface of T lymphocytes
(Biddison et al., 1983). Variation in the levels of
expression of class II antigens and differences in the
expression ofproducts ofthe differentclass II loci, are
likely to influence cellular interactions in the immune170 K. GUY et al.
system. Since class II antigens are also expressed on
non-lymphoid tissues, including vascular endothelia
(Gronewegen et al., 1985; Muller et al., 1985) these
effectsmaybemorewidespread than isatfirstevident.
It is conceivable that some cellular
interactions involving class II antigens might
predispose to the activation of T lymphocytes with
suppressor activity (Palacios et al., 1983; Pawelec et
al., 1984). This would be a normal function of
cellular immunity but could also be a contributory
factor to the pathogenesis of malignancy of the B
cell series. Among normal cells, both quantitative
and qualitative differences in class II expression
have functional consequences. For example, the
ability of monocytes to present antigen to T cells
correlates with the coordinate expression of DR
and DQ antigens (Gonwa et al., 1983). Class II-
dependent allogeneic stimulation of T cells by
monocytes is a function of quantitative variation in
class II expression on the stimulator population
(Nunez et al., 1985). In this regard, cells from CLL
patients are inefficient stimulators of allogeneic T
lymphocytes (Halper et al., 1979), unless the cells
are first cultured with TPA (Okamura et al.,
1982b).
The growth and differentiation of B cells involves
secretion of specific factors by T lymphocytes
(reviewed by Howard & Paul, 1983) which bind to,
and induce the maturation of the cells. Activation
of B cells, and their entry into the cell cycle from a
resting state, involves substantial increases in class
II expression in both normal (Kehrl et al., 1985)
and, as shown here, in malignant populations. Is
increased cell surface class II expression on TPA-
treated CLL cells a stimulus for T cell activation
and subsequent synthesis of B cell growth and
differentiation factors? Some findings suggest that
this may be so. The TPA-induced differentiation of
CLL cells which is characterized by morphological
change, immunoglobulin secretion and cell cycle S
phase entry (Gordon, 1984) is dependent on
autologous helper T lymphocytes (Danersund et al.,
1985). TPA-induced increases in class II expression
are T cell independent (unpublished results). In
preliminary experiments we find that S phase entry
of CLL cells, which occurs after several days of
culture with TPA, is blocked by some anti-class II
monoclonal antibodies. This suggests that inter-
actions of class II antigens on TPA-treated CLL
cells with T cells may lead to activation of the T
cells, and perhaps induction of B cell growth and
differentiation factor synthesis. Therefore it is
possible that deficiencies of expression of class II
antigens in B cell malignancy contribute primarily
to the pathogenesis of malignant disease, because of
failure of the malignant cells to activate T lympho-
cytes in vivo. However, this requires much further
analysis. An obvious difficulty in proposing
deficiencies of class II expression as a mechanism
contributing to the maturation arrest of malignant
B cells, is that many cases of CLL and NHL have
coordinate expression of class II antigens and very
substantial quantities of the antigens at the cell
surface. In the absence of additional anomalies
affecting the ability of the cells to respond to
differentiation signals, this would appear to be
incompatible with a possible failure to activate T
cells.
It is possible that determining the class II
phenotypes of cells from leukaemia and lymphoma
patients may be of some prognostic significance. It
will be necessary to evaluate this by monitoring the
survival of a number of patients with different
patterns of class II expression over a long period of
time. However, in the short term there does not
appear to be any significant diagnostic or
prognostic value in determining class II phenotypes,
except perhaps in aiding the histopathological
classification of non-Hodgkin's lymphoma. The
class II phenotypes of some CLL patients are very
stable with time (Guy et al., 1986a) and are
apparently unaffected by treatment of the disease.
The results of analysis of class II expression in
CLL (and also in some normal tissues) imply that
there may be independent regulatory elements for
the different class II genes. This is in contrast to
other studies which imply that the regulation of
expression of products of the different class II genes
is coordinate (Mach et al., 1984). Furthermore, the
expression of DQ antigens does not occur in
malignant B cells unless there is also DR
expression. This may suggest that there are
regulatory mechanisms for DQ antigens which are
inherent to the DR genes. The ability of CLL cells
to respond with much increased class II expression
after stimulation with TPA, will be of use in
detailed molecular studies and the availability of
large numbers of B cells from CLL patients will
greatly help examination of the mechanisms of class
II antigen regulation.
Further studies of cells from patients with B cell
leukaemia and lymphoma will provide much
valuable information on the structure and function
of class II antigens, and this will be relevant to an
understanding of the mechanisms governing their
expression in normal tissues. The possible role of
class II antigens in stimulating autologous cellular
interactions, leading to the synthesis of growth and
differentiation factors for normal B cells is crucial
also to the understanding of failures of malignant
B cell differentiation. With this knowledge the
significance of anomalous expression of MHC class
II antigens in the pathogenesis of B cell malignant
disease may be revealed.MHC CLASS II ANTIGENS IN B CELL MALIGNANCY 171
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